The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
Open accessAbstract
The objective of this study was to determine the safety, kinetics and dosimetry of 177Lu labeled prostate specific membrane antigen (PSMA) small molecules 177Lu-PSMA-I&T and 177Lu-PSMA-617 in a large cohort of patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing PSMA radioligand therapy (PRLT). Methods: A total of 138 patients (mean age, 70±9 y; age range 46-90 y) with progressive mCRPC and PSMA expression verified by 68Ga-PSMA-11 PET/CT underwent PRLT. 51 patients received 6.1±1.0 GBq (range, 3.4-7.6 GBq) 177Lu-PSMA I&T and 87 patients received 6.5±1.1 GBq (range, 3.5-9.0 GBq) 177Lu-PSMA-617. Dosimetry was performed in all patients on the identical protocol. The mean absorbed doses were estimated with OLINDA software (MIRD Scheme). Treatment-related adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Results: The whole-body half-lives were shorter for 177Lu PSMA I&T (35 h) as compared to 177Lu PSMA-617 (42 h). The mean whole-body dose of 177Lu-PSMA-617 was higher as compared to 177Lu-PSMA-I&T (0.04 Gy/GBq vs. 0.03 Gy/GBq, p<0.00001). Despite the longer half-life of 177Lu-PSMA-617, the renal dose of 177Lu-PSMA-617 was lower than for 177Lu-PSMA-I&T (0.77 Gy/GBq vs 0.92 Gy/GBq, P = 0.0015). Both PSMA small molecules demonstrated a comparable dose to parotid glands (0.5 Gy/GBq, P = 0.27). Among all normal organs, lacrimal glands exhibited the highest mean absorbed dose of 5.1 Gy/GBq and 3.7 Gy/GBq for 177Lu-PSMA-617 and 177Lu-PSMA I&T, respectively. All tumor metastases exhibited a higher initial uptake when using 177Lu-PSMA I&T, as well as shorter tumor half-life as compared to 177Lu-PSMA-617 (p<0.00001). The mean absorbed tumor doses were comparable for both 177Lu-PSMA I&T and 177Lu-PSMA-617 (5.8 Gy/GBq vs. 5.9 Gy/GBq, P = 0.96). All patients tolerated the therapy without any acute adverse effects. There was a small, statistically significant reduction in hemoglobin, leukocyte counts and platelet counts after 177Lu-PSMA-617 and 177Lu-PSMA I&T which did not need any clinical intervention. No nephrotoxicity was observed after either 177Lu-PSMA I&T or 177Lu-PSMA-617 PRLT. Conclusion: Both 177Lu-PSMA I&T and 177Lu-PSMA-617 PRLT demonstrated favorable safety in mCRPC patients. Highest absorbed dose amongst healthy organs were observed for the lacrimal and parotid glands, however, not resulting in any significant clinical sequel. 177Lu-PSMA-617 demonstrated higher whole-body and lacrimal glands absorbed dose, but lower renal doses as compared to 177Lu-PSMA-I&T. The mean absorbed tumor doses were comparable for both 177Lu-PSMA I&T and 177Lu-PSMA-617. There was a large inter-patient variability of the dosimetry parameters. Therefore, individual patient-based dosimetry seems favorable for personalized PRLT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00237-3 · Cited by 1,170
Violet, J., Jackson, P., Ferdinandus, J., Sandhu, S., Akhurst, T., Iravani, A., Kong, G., Kumar, A. R., Thang, S. P., Eu, P., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.219352 · Cited by 504
Delker, A., Fendler, W. P., Kratochwil, C., Brunegraf, A., Gosewisch, A., Gildehaus, F. J., Tritschler, S., Stief, C. G., Kopka, K., Haberkorn, U., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3174-7 · Cited by 322
Violet, J., Sandhu, S., Iravani, A., Ferdinandus, J., Thang, S.-P., Kong, G., Kumar, A. R., Akhurst, T., Pattison, D., Beaulieu, A., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.236414 · Cited by 292
Okamoto, S., Thieme, A., Allmann, J., D’Alessandria, C., Maurer, T., Retz, M., Tauber, R., Heck, M. M., Wester, H.-J., Tamaki, N., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178483 · Cited by 213
PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer
Kratochwil, C., Giesel, F. L., Leotta, K., Eder, M., Hoppe-Tich, T., Youssoufian, H., Kopka, K., Babich, J. W., & Haberkorn, U. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.147181 · Cited by 117
Cited by
Hennrich, U., & Eder, M. (2022) · Pharmaceuticals · doi:10.3390/ph15101292 · Cited by 318
Kratochwil, C., Fendler, W. P., Eiber, M., Hofman, M. S., Emmett, L., Calais, J., Osborne, J. R., Iravani, A., Koo, P., Lindenberg, L., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06255-8 · Cited by 299
Self-citationMuniz, M., Loprinzi, C. L., Orme, J. J., Koch, R. M., Mahmoud, A. M., Kase, A. M., Riaz, I. B., Andrews, J. R., Thorpe, M. P., Johnson, G. B., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102748 · Cited by 35
Mattana, F., Muraglia, L., Barone, A., Colandrea, M., Saker Diffalah, Y., Provera, S., Cascio, A. S., Omodeo Salè, E., & Ceci, F. (2024) · Cancers · doi:10.3390/cancers16091643 · Cited by 16
Metadata
- Authors
- Schuchardt, C., Zhang, J., Kulkarni, H. R., Chen, X., Müller, D., & Baum, R. P.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2021-12-09
- Volume
- 63
- Issue
- 8
- Pages
- 1199-1207
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W4200227314
- Cited by
- 187
- References
- 7
- FWCI
- 12.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry. https://app.cochat.ai/papers/10.2967/jnumed.121.262713
- The paper
- Schuchardt, C., Zhang, J., Kulkarni, H. R., Chen, X., Müller, D., & Baum, R. P. (2022). Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.121.262713
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.